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The mechanisms that underlie the potent Th1-adjuvant capacity of poly(methyl vinyl ether-co-maleic anhy-
dride) nanoparticles (NPs) were investigated. Traditionally, polymer NPs have been considered delivery
systems that promote a closer interaction between antigen and antigen-presenting cells (APCs). Our results
revealed that poly(anhydride) NPs also act as agonists of various Toll-like receptors (TLRs) (TLR2, -4, and -5),
triggering a Th1-profile cytokine release (gamma interferon [IFN-], 478 pg/ml versus 39.6 pg/ml from
negative control; interleukin-12 [IL-12], 40 pg/ml versus 7.2 pg/ml from negative control) and, after incubation
with dendritic cells, inducing a 2.5- to 3.5-fold increase of CD54 and CD86 costimulatory molecule expression.
Furthermore, in vivo studies suggest that NPs actively elicit a CD8 T-cell response. Immunization with empty
NPs resulted in a significant delay in the mean survival date (from day 7 until day 23 postchallenge) and a
protection level of 30% after challenge against a lethal dose of Salmonella enterica serovar Enteritidis. Taken
together, our results provide a better understanding of how NPs act as active Th1 adjuvants in immunopro-
phylaxis and immunotherapy through TLR exploitation.
Vaccination and immunotherapy represent two of the major
advances in modern medicine. However, the quest for better
vaccines against pathogens, allergies, or cancer still remains a
challenge. Antigen variability and suboptimal immunogenicity
represent some of the crucial points that explain incomplete
protection, and new vaccines will have to overcome these
points. Currently numerous studies of the topic of new vacci-
nation strategies are being carried out (9, 12).
Subunit vaccines represent one of these approaches since
they have the potential to develop specific responses and entail
the added benefits of allowing the incorporation of different
antigens in a single vaccine (4, 5, 10, 51, 54). In addition,
subunit vaccines avoid the infection risk of live attenuated and
recombinant vaccines. However, they are poorly immunogenic
and require the use of adjuvants (40). Within them, the alum
salts, which are known to polarize the response toward Th2,
have been the only approved adjuvants for human use for
almost 1 century (7, 28). Currently new adjuvants are being
approved, such as ASO4, included in Cervarix, a human pap-
illomavirus vaccine (GlaxoSmithKline), containing Al(OH)3,
and the immunomodulator 3-O-desacyl-4monophosphoryl
lipid A (MPL). Additionally, another adjuvant, MF59, has
been approved in Europe for human use and is found in sev-
eral vaccines, such as an influenza vaccine (37). Although it
was initially referred to as a Th2-bias adjuvant (57), it was later
defined as a Th0 adjuvant, which enhances whichever response
is present, without biasing the profile (38).
The main challenges, such as immunotherapy against aller-
gies and tumors or immunoprophylaxis against intracellular
pathogens, require Th1 responses in order to be effective. For
this reason a number of adjuvants that display the ability to
bias the immune response toward the right Th profile are being
investigated (8, 22, 50, 59).
Particulate delivery systems belong to the category of adju-
vants that facilitate antigen uptake by antigen-presenting cells
(APCs) or by increasing the influx of professional APCs into
the injection site (21). Among the different types of particu-
lated delivery systems, polymer nanoparticles (NPs) are a
group of delivery systems with interesting abilities as adjuvants
for both conventional and mucosal vaccination (29). Poly(an-
hydride) NPs made by the copolymer of methyl vinyl ether and
maleic anhydride have demonstrated their efficacy as adjuvants
in inducing Th1 immune responses (16, 17, 47–49). Poly(anhy-
dride) NPs are actually licensed in the United Kingdom for
oral drug delivery (46) and have proven adjuvant capacities in
mentioned and other routes. Nanoparticles can enhance the
delivery of the loaded antigen to the gut lymphoid cells due to
their ability to be captured and internalized by cells of the
gut-associated lymphoid tissue (GALT). Furthermore, these
delivery systems offer a number of extra advantages, including
controlled release properties (15). However, the ability of NPs
to actively take part in immune potentiation through direct
modulation of immune system cells had never been studied.
In the past few years, several immunostimulatory adjuvants
have proved to be able to stimulate innate responses through
the engagement of pathogen-associated molecular pattern
(PAMP) receptors (PRR) initiating, amplifying, and directing
the specific response (18, 19, 33, 39, 41, 56). PRR receptor
families include the Toll-like receptors (TLRs), whose rela-
tionship to innate/adaptive immunity has been demonstrated
widely (11, 18, 22, 26, 33, 34). TLR engagement has been
shown to regulate the function of APCs, leading to the upregu-
lation of costimulatory molecules, such as CD80 and CD86,
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and adhesion molecules that improve antigen presentation.
TLRs are linked via adapter molecules to intracellular signal-
ing pathways that generally lead to transcription of NF-B
target genes, such as cytokine genes that will modulate the
immune response.
TLRs recognize conserved molecular motifs that are shared
by infectious agents but which are absent in the host. Thus,
TLR4 is the cell-based PRR that recognizes lipopolysaccha-
rides (LPS) from Gram-negative bacteria (with LPS binding
protein and cell surface CD14 as coreceptors). Bacterial pep-
tidoglycan and lipopeptides are recognized by TLR2 in com-
bination with TLR1 or TLR6. Flagellin is recognized by TLR5,
CpG-containing DNA is recognized by TLR9, the TLR3 signal
is in response to double-stranded RNA, and the TLR7 and
TLR8 signals are in response to certain single-stranded RNA.
Therefore, not only exogenous but also endogenous ligands
have been shown to act as TLR activators (45). In addition to
natural ligands, nonmicrobial, xenobiotic, or artificial ligands
for these TLRs have been described (31). Therefore, our hy-
pothesis was that poly(anhydride) NPs might act as an agonist
of some TLRs in order to explain the mechanisms that under-
lay their potent Th1-adjuvant capacity (17, 35, 47–49).
In this study, the TLR ligation and the expression of co-
stimulatory molecules and cytokine secretion by dendritic cells
(DCs) after incubation with poly(anhydride) NPs were studied.
Further, we studied the T-cell activation abilities of NP and
ovalbumin (OVA) coadministration, evaluating T-CD4 and
T-CD8 responses. Results revealed the NP-mediated enhance-
ment of some TLRs that may be involved in the immune
adjuvant properties of these particular delivery systems.
MATERIALS AND METHODS
Preparation of PVM/MA nanoparticles. Poly(anhydride) NPs were prepared
by a modification of the solvent displacement method (3). Briefly, 100 mg
poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer were dis-
solved in 6 ml acetone. The acetone-copolymer mixture was poured into a
solution containing 0.2 g mannitol in 5.8 ml of double-deionized water (H2Odd).
All solvents were evaporated under reduced pressure by spray drying (mini-spray
dryer; Bu¨chi, Switzerland).
Characterization of nanoparticles. The size and zeta potential of nanopar-
ticles were determined by photon correlation spectroscopy and electrophoretic
laser Doppler anemometry, respectively, employing a Zetamaster analyzer sys-
tem (Malver Instruments Ltd., Worcestershire, United Kingdom). The diameter
of the nanoparticles was determined after dispersion in ultrapure water (1:10)
and measured at 25°C with a dynamic light scattering angle of 90°C. The zeta
potential was determined as follows: 200 l of the samples were diluted in 2 ml
of a 0.1 mM KCl solution adjusted to pH 7.4 (25). The average particle size is
expressed as the volume mean diameter (Vmd) in nanometers (nm), and the
average surface charge as mV.
Differentiation of mouse dendritic cells from mouse femur bone marrow
precursors. Bone marrow dendritic cells (BMDC) were generated as follows:
bone marrow from BALB/c mouse femur and tibia was extracted, and erythro-
cytes were lysated in ammonium chloride potassium (ACK) lysing buffer for 1
min (NH4Cl, 0.15 M; KHCO3, 10 mM; Na2 EDTA, 0.1 mM). Obtained cells were
then washed by centrifugation in RPMI 1640 medium. The lymphocyte and
granulocyte populations were then depleted by coincubation with 50 g/ml of
rabbit complement (Sigma Chem. Co.) and an antibody mixture against CD4
(GK1-5 hybridoma, 100 g/ml), CD8 (H35.17.2 [142] hybridoma, 100 g/ml),
Ly-6G/Gr1 (10 g/ml), and CD45R/B220 (50 g/ml). (All reagents were from
BD Pharmingen.) The mixture was incubated at 37°C for 50 min. After deple-
tion, cells were washed, and all remaining cells were harvested in 24-well plates
at 106 cells/ml. The medium (RPMI 1640 with 10% fetal calf serum [FCS], 2 mM
glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 5  105 mM
2-mercapthoethanol) was supplemented with 20 ng/ml of mouse granulocyte/
macrophage colony-stimulating factor and interleukin 4 (IL-4) (Prepotech, Lon-
don, United Kingdom) at 37°C and in 5% CO2. At days 2 and 5, two-thirds of the
medium was replaced with fresh cytokine-supplemented medium. On the 7th
day, in vitro assays for BMDC maturation markers were carried out by adding
500, 100, 20, and 4 g/ml of poly(anhydride) NPs along with negative controls.
Forty-eight hours later, supernatants were collected, and IL-12 (p70) and tumor
necrosis factor alpha (TNF-) measured by enzyme-linked immunosorbent assay
(ELISA) (BD Pharmingen), according to the manufacturer’s instructions. Fi-
nally, all cells were harvested and analyzed by flow cytometry by using anti-CD54
(clone 3E2), anti-CD86 (clone GL1), anti-CD11c (clone HL-3), and for the
unspecific bind measurement, mouse fluorescein isothiocyanate (FITC)-labeled
IgG1 (clone MOPC-21), at 4°C for 15 min. All reagents originated from BD
Pharmingen. Then cells were washed, acquired on a FACScan cytometer (BD
Biosciences), and analyzed using Cell Quest software (BD Biosciences). Finally,
the gating was selected by comparison with positive and negative controls. The
mean fluorescence intensity (MFI) of the control isotype (IgG1) was subtracted
from the fluorescence data of its own group and then referred to the fluorescence
of the negative control for the analyzed maturation marker, as follows: increase
level  (sample MFImarker  sample MFIIgG1)/(untreated MFImarker  un-
treated MFIIgG1).
In vivo killing. The system used to detect cytotoxic T lymphocyte (CTL)
responses elicited after OVA-NP immunization is based on antigen presentation
of OVA peptides on major histocompatibility (MHC) class I molecules. In vitro
restimulation of splenic cells is performed with a specific OVA peptide charac-
terized by its specific recognition MHC class I molecule. Thus, C57BL/6 mice
were intraperitoneally (i.p.) immunized with 4 mg of empty poly(anhydride) NPs,
10 g of OVA, or both 4 mg of NP and 10 g OVA in different injection sites
to reduce adsorptions. Due to the high ability of poly(anhydride) NPs to bind the
amino-terminal part of proteins, NPs and OVA were administered in different
sites of the abdomen, reducing possible OVA coating of poly(anhydride) NPs. At
day 7, spleens from naïve mice were extracted and smashed, and erythrocytes
lysed in ACK buffer. Resulting splenocytes were treated in the presence or in the
absence of 10 g/ml of the SIINFEKL peptide (encompassing the immunodom-
inant H-2b-restricted CTL epitope from ovalbumin [amino acids 257 to 264],
produced by Neomps, Strasbourg, France) for 30 min at 37°C. Splenic cells were
then differentially labeled with 2.5 M (SIINFEKL-pulsed targets) or 0.25 M
(nonpulsed splenocytes) of 5-(6)-carboxyfluorescein diacetate N-succinimidyl es-
ter (CFSE) for 15 min at room temperature and used as target cells to detect in
vivo cytotoxic activity. A dose of 107 cells per mouse (50% CFSE high and 50%
CFSE low) was intravenously (i.v.) injected into the naïve and immunization
groups. After 24 h spleens were removed, and the high-versus-low-CFSE lym-
phocyte population ratio was analyzed by flow cytometry. All lysis values corre-
spond to triplicate samples. Specific lysis was calculated as follows: % specific
lysis 100 {[% splenocytes CFSE high (from immunized mice)/% splenocytes
CFSE low (from immunized mice)]/[% splenocytes CFSE high (from nonimmu-
nized mice)/% splenocytes CFSE low (from nonimmunized mice)]}  100.
Specific IFN- production. To measure the production of gamma interferon
(IFN-) in response to SIINFEKL, splenocytes from mice collected at day 8 after
immunization were plated on 96-well plates at 8  105 cells/well with culture
medium (CM) alone or with 30 M SIINFEKL in a final volume of 0.25 ml of
CM. Supernatants (50 l) were removed 48 h later, and IFN- was measured by
enzyme-linked immunospot (ELISPOT) assay (BD Pharmingen) according to
the manufacturer’s instructions.
TLR screening. LPS-free empty NPs were shipped to Invivogen (France) to
assay their capacity to stimulate TLR signaling. Briefly, samples and controls
were tested on recombinant HEK293 cell lines that functionally overexpress a
given TLR protein as well as a reporter gene which is a secreted alkaline
phosphatase. The production of this reporter gene is driven by a NF-	-induc-
ible promoter. Nanoparticles were incubated at 500 g/ml, the highest nontoxic
concentration, as recommended by Invivogen. Known TLR agonists used as
positive controls include PAM2 (100 ng/ml) for TLR2; poly(I:C) (100 ng/ml) for
TLR3; Escherichia coli K12 LPS (1 g/ml) for TLR4; flagellin (1 g/ml) for
TLR5; R848 (10 g/ml) for TLR7 and TLR8, and ODN 2006 (10 g) for TLR9.
All results are given as optical density (OD) values.
Protection studies of mice. Phosphate-buffered saline (PBS) or empty poly-
(anhydride) NPs were administered to groups of 10 BALB/c mice. Ten days after
administration, mice were i.p. infected with a lethal dose of Salmonella enterica
serovar Enteritidis in stationary phase (1.6  102 CFU, in 100 l phosphate-
buffered saline). The number of dead mice after challenge was recorded daily.
All mice were treated in accordance with institutional guidelines for treatment of
animals (Ethical Committee for the Animal Experimentation, CEEA, of the
University of Navarra).
IFN- and IL-4 release from splenic cells. In order to determine the degree of
activation of the two subset Th1/Th2 populations in immunized mice, IFN- and
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IL-4 release from splenic cells was determined. Three animals immunized with
PBS or poly(anhydride) NPs were sacrificed at day 10 by cervical dislocation, and
spleens were removed and placed in RPMI 1640 media (Gibco-BRL, Paisley,
United Kingdom) under sterile conditions. Spleens were smashed in tissue cul-
ture dishes and centrifuged (400  g, 10 min), the supernatant was discarded,
and the sediment was washed twice in phosphate-buffered saline. The cellular
pellet was resuspended in 2 ml RPMI 1640-HEPES medium (Gibco-BRL) sup-
plemented with 500 l of antibiotic-antimycotic solution (Sigma) and 10% (vol/
vol) fetal bovine serum. In a 24-well microtiter plate (Costar, NY), cell suspen-
sions were added at 800,000 cells/well, along with Salmonella serovar Enteritidis
heat extracts (HE) at 100 g/well (36). Negative controls without HE were also
included. All wells were set up in duplicate. Cells were incubated (37°C, 48 h, 5%
CO2), supernatants were collected, and the levels of IFN- and IL-4 released
determined with a commercial sandwich ELISA kit (Biosource, Camrillo, CA).
Statistical analyses. When required, the nonparametric Kruskal-Wallis test,
followed by the Mann-Whitney U test, was used. Statistically significant differ-
ences were considered when P was 
0.05. All data processing was performed
using the GraphPadPrism 5 software.
RESULTS
Dendritic cell costimulatory molecule increase triggered by
nanoparticles. Nanoparticle formulations displayed a homoge-
neous volume mean diameter of 230  5 nm, with a low
polydispersity index. In addition, poly(anhydride) NPs dis-
played an electronegative surface charge with a Zeta potential
value of 36  2 mV.
After the differentiation of BMDC, an analysis of CD54 and
CD86 markers was performed in order to confirm the induc-
tion of positive maturation triggered by NPs. Flow cytometry
studies showed that incubation of 4 g/ml of poly(anhydride)
NPs induced 2.3- and 2.4-fold increases of expression of both
CD54 and CD86, respectively, compared with BMDC incu-
bated with medium alone (Fig. 1). When the concentration of
empty NP was raised to 20 g/ml, the expression of the co-
stimulatory molecule CD54 reached a 3.6-fold increase relative
to the negative control.
Induction of cytokine production of BMDC by NP stimula-
tion. We then examined whether the NP stimulation was able
to stimulate bone marrow-derived DCs to produce the proin-
flammatory cytokine IL-12 or TNF-. It was found that NP
stimulation induced TNF- release in a dose-dependent man-
ner (Fig. 2A), varying from 27.8 pg/ml at 4 g/ml of NP to
478.7 pg/ml at 500 g/ml and being in all cases significantly
higher (P 
 0.001) than those found in supernatant from
nonstimulated cells. The analysis of IL-12 production revealed
also a dose-response pattern, being significant from 20 to 100
g/ml. A higher concentration of NP (500 g/ml) reduced the
IL-12 release to basal levels (Fig. 2B).
Cytotoxicity induced by NP uptake: in vivo killing. An in vivo
CTL assay was conducted to measure the capacity of NPs to
activate OVA-specific CD8 T cells using the specific SIIN
FEKL OVA peptide. C57BL/6 mice were immunized i.p. with
OVA (10 g), NP (4 mg), or a mixture of OVA and NP. At day
7 after immunization, mice were injected i.v. with a mixed
population of CFSE-labeled splenocytes. Twenty-four hours
after injection of the CFSE-labeled cells, splenocytes were
analyzed by flow cytometry for the presence of the two popu-
lations of CFSE-labeled cells. Results indicate that the specific
T-cell lysis response to SIINFEKL treatment was negligible in
the absence of the NP adjuvant. However, when lymphocytes
from mice immunized with NPs plus OVA were tested, the in
vivo specific CTL response against SIINFEKL was 41.2% 
16.5% (Fig. 3).
In addition to measuring the in vivo cytotoxicity, we also
measured by ELISPOT the number of IFN--producing cells
specific for the SIINFEKL peptide induced by immunization.
Thus, 7 days after immunization, splenic cells were restimu-
lated in vitro in the presence or absence of the SIINFEKL
peptide. The number of IFN- spots was counted to evaluate
the frequency of SIINFEKL-specific cytotoxic T cells. The
ELISPOT assay revealed IFN--producing OVA-specific cells
FIG. 1. Flow cytometric analysis of BMDC maturation markers.
Bars show the fold-increase of mean relative fluorescence over nega-
tive control of CD86 and CD54 after coincubation of BMDC with 500
g of NP, 100 g of NP, 20 g of NP, and 4 g of NP.
FIG. 2. Proinflammatory cytokine detection in supernatants of
BMDC. Levels of TNF- (A) and IL-12 (B) released to the BMDC
culture supernatant after 24 h of coincubation with 500 g of NP, 100
g of NP, 20 g of NP, and 4 g of NP. Nonstimulated controls are
also included. All values are shown as arithmetic means  standard
errors of the means (SEM) (n  3).
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from mice injected with OVA-NP (129.25  56.20 spot-form-
ing cells [SFC]/106 cells compared with 27.5  11.1 SFC/106
cells in the absence of peptide, P 
 0.05) (Fig. 4). In contrast,
IFN--producing splenocytes specific for the SIINFEKL pep-
tide were not detected in mice immunized with NPs or OVA
alone.
Nanoparticle-induced TLRs. In order to understand the ad-
juvant capacities shown by the poly(anhydride) NPs, their abil-
ity to trigger different TLR responses was measured. As shown
in Fig. 5, nanoparticles significantly activated hTLR2-,
hTLR4-, and hTLR5-expressing cell lines. In addition the
hTLR3 cell line was also weakly activated. The TLR cell line
was not stimulated at all. This cell line does not express any
TLR but still has an NF-	-inducible promoter. This result
confirmed that all measured OD values were strictly a conse-
quence of TLR stimulation.
Immunization and protection studies of mice against Sal-
monella serovar Enteritidis. Ten days after the intraperitoneal
administration of poly(anhydride) NPs, splenocytes showed a
basal expression of IFN- (20 pg/ml). Restimulation with an
antigenic complex containing LPS (HE, from S. Enteritidis)
resulted in a significative (P  0.001) increase in detected
IFN- (577 pg/ml). Nonimmunized animals showed no IFN-
release before restimulation and a very small amount (40 pg/
ml) after incubation with HE containing LPS. When IL-4 pro-
duction was measured, a very weak basal secretion was de-
tected for restimulated splenocytes in both the inoculated and
control groups (10 pg/ml).
Nanoparticle inoculation elicited a 30% protection against
lethal intraperitoneal challenge with S. Enteritidis (1.6  102
CFU) (Fig. 6). In addition, the end survival date was signifi-
cantly delayed (P 
 0.001) from day 7 for the control group
until day 23 for the treated animals.
FIG. 3. In vivo induction of CTL activity specific for SIINFEKL
peptide. C57BL/6 mice were immunized with OVA, poly(anhydride)
NPs, or OVA plus NP; 7 days after immunization, naïve mice were
sacrificed, and splenocytes coincubated in the presence or absence of
SIINFEKL. Pulsed cells were incubated in the presence of high levels
of CFSE, while nonpulsed cells were incubated with low levels of
CFSE. After administration of CFSE-high and CFSE-low splenocytes
to immunized mice, the specific cytotoxic activity against the SIIN
FEKL peptide was measured by an in vivo killing assay. The data
represent the mean percentage values from triplicate samples.
FIG. 4. In vivo induction of OVA-specific IFN--secreting CD8 T
cells. Mice were immunized with OVA, poly(anhydride) NPs, and
OVA plus NP and 8 days after immunization sacrificed. Splenocytes
were cultured in triplicate in the presence of SIINFEKL or culture
medium alone (negative control). Each bar represents the mean value
of SFC/106 cells.
FIG. 5. Effects of nanoparticles on the activation of TLR signaling.
Bars represent engagement to TLR2, TLR3, TLR4, TLR5, TLR7,
TLR8, and TLR9 after incubation with positive controls and poly(an-
hydride) NPs. Names inside the bars of positive controls represent the
specific agonist for each TLR used in the study: PAM2 (100 ng/ml) for
TLR2, poly(I:C) (100 ng/ml) for TLR3, E. coli K12 LPS (1 g/ml) for
TLR4, flagellin (1 g/ml) for TLR5, R848 (10 g/ml) for TLR7 and
TLR8, and ODN 2006 (10 g) for TLR9. A TLR nonexpressing
recombinant cell line is also included (TLR). Results are given in OD
values.
FIG. 6. Comparative protection against the virulent serovar of S.
Enteritidis. Groups of 10 BALB/c mice were i.p. immunized with
poly(anhydride) NPs () or PBS (E). Ten days later, mice were chal-
lenged i.p. with 1.6  102 CFU of the virulent strain 3934. Data are
expressed as percentage of survivals after challenge.
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DISCUSSION
The incorporation of antigens into poly(anhydride) NPs has
been demonstrated to enhance the immune responses in terms
of antibody production and overall protection levels (16, 17,
35). This fact may be explained by the implemented possibili-
ties that NPs render to the antigen: controlled release from the
vehicle and chemotaxis for APC recruitment. Besides, Gomez
et al. reported that after oral administration, the bioadhesive
nature of the polymer enhanced the interaction of poly(anhy-
dride) NPs with the gut mucosa (1, 16, 21). In addition, the
ability of nanoparticles to partially erode allows a controlled
release of the antigens that could favor their sustained expo-
sition to the immune system, increasing the efficiency of vac-
cination. In fact, we observed the formation of an antigen
depository after intradermal vaccination that increased antigen
residence time that, in turn, was translated into higher re-
sponses (I. Tamayo, C. Gamazo, J. deSouza, and J. M. Irache,
unpublished results). Moreover, these NPs allow the adhesion
of antigens and ligands to their outer shells, creating high-
density antigen surfaces that increase the possibilities of
antigen recognition and/or capture by the APCs. Based on
the ability of NPs to induce potent immune responses, our
hypothesis was that NPs are able to trigger determined
elements of the immune system. Explicitly, due to their
particulate nature, we hypothesized that NPs would interact
with APCs, specifically DCs, through PRRs, including TLR.
Of the receptors (PRR) that sense the plethora of “danger”
signals, TLRs represent one of the most prominent groups.
Not in vain, TLR engagement leads to DC activation and
promotes T-cell priming and acquired immunity. In addition, it
also activates microbicidal effects and inflammation in cells of
the innate immune system. It is well established that some
pathogen products, PAMPs, are the main natural actors in-
volved in the activation of DCs through PRR, resulting in a
defined maturation phenotype responsible for driving a polar-
ized Th1 or Th2 response. Thus, DCs are capable of integrat-
ing signals from pathogens, cytokines, and T cells, leading to
the generation of an adaptive immune response of the appro-
priate class (44). However, it has become clear that PRR may
sense nonmicrobial “patterns” (45), including polysaccharides
from plants (43), dietary fatty acid lipids (27), and some xeno-
biotic products used in pharmacotherapy (31). These include
synthetic ligands of TLR7, such as imiquimod, R848, and lox-
oribine (2), but the TLR family is also critical for the recogni-
tion of certain endogenous molecules (24). Indeed, TLR2 can
be activated by Hsp-60, -70, or -96 or by high-mobility group
protein B1 (HMGB1), whereas TLR4 can be triggered by
Hsp22, -60, -70, or -96, fibrinogen, HMGB1, hyaluronan frag-
ments, or by spliced exon encoding the type III repeat extra
domain A (EDA) from fibronectin as recently described (26).
When the potential of NPs to act as TLR ligands was
screened, we observed the high ability to stimulate TLR2 and,
to a lesser extent, TLR3, TLR4, and TLR5 signaling. In gen-
eral, the hydrophobicity of a PAMP is a crucial structural
parameter for receptor specificity (6). Therefore, we can as-
sume that NP polymer hydrophobicity is in the base of its TLR
agonist capacity. However, some specificity should drive the
specific activation; in fact, NP-mediated activation was a con-
sequence exclusively of TLR ligation as demonstrated by the
absence of TLR-cell line activation.
TLR2 appears to contain several epitopes that may interact
with ligands, potentially suggesting that different regions within
the molecule might contribute to the recognition of specific
agonists (30). Thus, TLR2 seems to be highly promiscuous,
able to recognize the most diverse set of nonrelated TLR2
agonists, most of them glycolipids, lipopeptides, or glycosyl-
phosphatidylinositol (GPI)-anchored structures (58). Even
some other polymers used in nanotechnology, such as alginate
polymers, have been reported to be potent immune-stimulat-
ing agents in eliciting cytokine production by monocytes
through TLR (14). The authors of this report suggested that
short oligosaccharides from alginates serve as agonists for
TLR2 and TLR4. Some alginate-derived neoglycolipids have
also been described as potent ligands for TLR4 (60). It is
noteworthy that many of the structurally defined nonbacterial
agonists for TLR2 share a diacylglycerol group for which TLR2
has a structurally defined hydrophobic binding pocket (52).
However, from the strict structural point of view, many of the
PAMPs published for TLR2 have almost nothing in common.
It has been also suggested that the promiscuity of TLR2 is
linked to the fact that TLR2 interacts with other receptors,
such as TLR1, TLR6, CD36, or dectin-1 (61). However, our
results did not show TLR1 or TLR6 activation, rather a TLR4
activation. Agonists for TLR4 may be related to TLR2 agonists
since both may require acylated saturated fatty acids in their
molecules. Thus, some kind of promiscuity has been related
also to TLR4, with a growing list of ligands (23). Similarly,
TLR5 can signal as a homodimer, but it can also build a
heterodimer with TLR4, which results in the activation of an
alternative downstream signaling pathway (32).
Napolitani et al. (34) identified a “combinatorial code” by
which DCs promote Th1 responses, describing that synergistic
TLR stimulation is probably the rule. So, our hypothesis is that
the NP is able to bind to APC via proximal TLR, leading to the
assembly of membrane signaling complexes and the recruit-
ment of the cytoplasmic protein MyD88, which triggers the
activation of the transcription factor NF-B, which induces the
expression of TH1-derived cytokine genes (20).
To evaluate this hypothesis of the effect of TLR synergy on
Th1 priming, we stimulated DCs with NP and tested their
capacity to trigger CD86 and CD54 costimulatory molecule
expression. Results demonstrated not only the high expression
of these costimulatory molecules but also the secretion of Th1-
derived cytokines from DCs. One of the most important char-
acteristics that place DCs as key players is their ability to
decode and integrate danger signals that are transported in a
mature state to the T-cell areas, initiating an immune response
(42). As a result of an effective interaction, the DCs undergo a
maturation process. Thus, the analysis of the so-called signal 3,
with regard to the treatment with poly(anhydride) NPs, re-
vealed a significant increase of TNF- expression that followed
a dose-response pattern. Additionally, the detected levels of
IL-12 were also significantly increased, as a consequence of
coincubation with NPs. IL-12 from DCs is a key marker in the
innate responses that drive Th1 polarization (55). It is, then,
plausible to suppose that detection of both cytokines endorses
the hypothesis of TLR stimulation. Nevertheless, to address
speculations about beneficial effects of TLR signaling, a more
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detailed examination, including one of a TLR knockout system
(2, 4, 5), remains to be performed.
After confirming positive in vitro DC maturation and cyto-
kine expression, we analyzed the ability of NPs to induce an in
vivo cellular response. Studies performed with the model
OVA-peptide SIINFEKL showed that the coadministration of
empty NPs with OVA resulted in the induction of cytotoxic
T cells specific for target cells displaying OVA. Similarly,
ELISPOT assays revealed the presence of IFN--producing
cells in response to stimulation with the SIINFEKL peptide in
splenocytes from mice immunized with NPs and OVA, indi-
cating that NPs may be considered an adjuvant for the induc-
tion of CD8 T-cell immune responses.
All together, these results agree with previous observations
that suggested the potent immunostimulating nature of these
NPs. Estevan et al. (13) described that inoculation of mice with
empty NPs induced a significant level of protection against a
challenge with Salmonella enterica serovar Abortusovis. In fact,
we performed an experiment with empty nanoparticles in or-
der to test their ability to induce a protective response against
a lethal challenge with Salmonella serovar Enteritidis. Results
demonstrate a level of protection time compatible with the
activation immune response, as discussed above, with a signif-
icant delay in the mean survival date of treated mice from day
7 until day 23 postchallenge. For the particular case of Salmo-
nella infections, the first stages postimmunization were shown
to be nonspecific even when immunized with live vaccines (53).
In addition, as a facultative intracellular pathogen, T cell-
mediated immunity is required for clearance of the pathogen.
The pattern of cytokines released after NP inoculation is con-
sistent with the hypothesis that NPs activate an innate response
mediated by PRRs, enough to control the growth of bacteria
until the establishment of the proper T cell.
Classically, nanoparticles are being exploited as antigen de-
livery systems, but a more active role may be behind their
adjuvant properties. The results described here suggest an
active interaction of NP with DCs that will render multiple
stimuli mediated by PRRs, which might allow a more effective
response. Taken together, our results shed light on how NPs
act as active Th1 adjuvants in immunoprophylaxis and immu-
notherapy (10, 16, 17, 35). More information on NP recogni-
tion, intracellular trafficking, and processing in DCs would help
us to establish a greater degree of accuracy in this matter.
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